We are excited to announce that the EndoPredict test, a leading prognostic tool for early-stage breast cancer, is now available in Australia with NATA accreditation.

This marks a significant step forward in providing Australian patients with cutting-edge genomic technology for personalized breast cancer care.

EndoPredict is specifically designed for patients with early-stage ER+/HER2- breast cancer, offering a highly personalized risk assessment for disease relapse.

With this genomic test, Australian healthcare providers can now offer their patients deeper insights, helping them in finding the most appropriate path for managing their disease

The availability of EndoPredict in Australia empowers patients by providing precise, clinically validated data that is tailored to their unique cancer profile.

NATA Accreditation, a Stamp of Quality for Australian Labs:

• The National Association of Testing Authorities, Australia (NATA), has accredited Australian Clinical Labs to process the EndoPredict test.
• This accreditation guarantees the highest standards in accuracy, reliability, and quality.
• Australian patients and clinicians can now trust that their EndoPredict results meet stringent local standards.

Medicare Benefits Schedule (MBS) Reimbursement:

• EndoPredict is now accessible on the Medicare Benefits Schedule (MBS) for eligible patients with early-stage breast cancer, offering a partial rebate.
• This inclusion greatly improves access to this advanced diagnostic tool, ensuring that more Australian breast cancer patients can benefit from its use.

What This Means for Australian Patients and Healthcare Providers:

• Personalized Care: EndoPredict provides a clear, individualized prognosis
• Local Processing with NATA Accreditation: Assurance of quality, accuracy, and reliability through Australian Clinical Labs.
• Improved Access: With Medicare rebate options, the test is now more financially accessible for eligible patients.

Eurobio is committed to continuing our work with in-country laboratories to support clinicians and patients in making the best decisions for their care with confidence in the data they receive.

To learn more or get access to EndoPredict in Australia, contact Australian Clinical Labs or reach out to us at info-int@eurobio-scientific.de.

About us: Eurobio Scientific is a global company with a mission to improve patients’ quality of life through specialty diagnostics. Our vision is to become a leading global specialty diagnostics company by offering highly innovative solutions to healthcare professionals to serve this purpose.

With more than 370 employees worldwide, Eurobio Scientific is dedicated to providing local support through our four manufacturing centers, three research centers, and local offices in France, The Netherlands, Germany, Italy, Switzerland, the UK, and the USA.

Our expert R&D team gather years of experience in developing advanced molecular diagnostic tests in the fields of transplant, oncology, and infectious diseases.